Effect of Noninvasive Brain Stimulation on Hypokinetic Dysarthria in Parkinson’s Disease

Overview

Hypokinetic dysarthria (HD) is common in Parkinson's disease (PD) patients and responds only partially to pharmacotherapy and surgery. The investigators will explore long-term effects of repetitive transcranial magnetic stimulation (rTMS) applied over right superior temporal gyrus, brain area known to be engaged in the feedback control of voiced speech. The project results will allow for the identification of potential therapeutic effects of rTMS as a tool that could contribute to the speech therapy of HD in PD patients. The results will also enhance our understanding of brain mechanisms underlying specific long-term effects of rTMS.

Full Title of Study: “Effect of Noninvasive Brain Stimulation on Hypokinetic Dysarthria and Brain Plasticity in Parkinson’s Disease”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Outcomes Assessor)
  • Study Primary Completion Date: January 30, 2020

Detailed Description

A two parallel group, randomized, placebo controlled design will be used. Twenty PD patients will be stimulated in a two weeks long therapeutical sessions (10 sessions). Other twenty PD patients will be stimulated with the same protocol using sham stimulation. An MRI protocol consisting of T1, EPI BOLD, and DTI (diffusion tensor imaging) sequences and speech evaluation (acoustic signal processing and 3F test) will be performed prior to and after 10 days of rTMS and then repeated after 4, 8 and 12 weeks.

Interventions

  • Device: Transcranial magnetic stimulation- sham rTMS
    • Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
  • Device: Transcranial magnetic stimulation- real rTMS
    • Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.

Arms, Groups and Cohorts

  • Active Comparator: PD patients with real rTMS
    • Patients will receive real rTMS in a two weeks long sessions (10 sessions).
  • Sham Comparator: PD patients with sham rTMS
    • Patients will receive sham rTMS in a two weeks long sessions (10 sessions).

Clinical Trial Outcome Measures

Primary Measures

  • Changes in score of the 3F Test (the unabbreviated title- “the 3F Test Dysarthric Profile”)
    • Time Frame: On the beginning of the study, after completion of two weeks stimulation, 4,8 and 12 weeks after completion of stimulation sessions.
    • The 3F Test Dysarthric Profile enables clinicians to characterize a wide range of signs and symptoms of dysarthria. The minimum value of this scale is 0 (anarthria), the maximum value is 90 (no disorder). Higher scores of this scale mean better outcome. This test will be administrated by speech pathologist.

Secondary Measures

  • Resting state
    • Time Frame: On the beginning of the study, after completion of two weeks stimulation, 4,8 and 12 weeks after completion of stimulation sessions.
    • The effect of stimulation on the resting state networks will be studied using fMRI measurement.

Participating in This Clinical Trial

Inclusion Criteria

  • patients with clinically established PD (Postuma et al. 2016) Exclusion Criteria:

  • psychiatric disorders, including major depression, hallucinations – any MRI-incompatible metal in the body – epilepsy – lack of cooperation – presence of dementia

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Masaryk University
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.